PRIVIA HEALTH GROUP INC (PRVA) Fundamental Analysis & Valuation
NASDAQ:PRVA • US74276R1023
Current stock price
21.52 USD
+0.28 (+1.32%)
At close:
21.52 USD
0 (0%)
After Hours:
This PRVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PRVA Profitability Analysis
1.1 Basic Checks
- In the past year PRVA was profitable.
- In the past year PRVA had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: PRVA reported negative net income in multiple years.
- In the past 5 years PRVA always reported a positive cash flow from operatings.
1.2 Ratios
- PRVA's Return On Assets of 1.67% is in line compared to the rest of the industry. PRVA outperforms 54.00% of its industry peers.
- Looking at the Return On Equity, with a value of 3.11%, PRVA is in line with its industry, outperforming 58.00% of the companies in the same industry.
- PRVA has a Return On Invested Capital (2.75%) which is comparable to the rest of the industry.
- The Average Return On Invested Capital over the past 3 years for PRVA is significantly below the industry average of 8.86%.
- The 3 year average ROIC (2.17%) for PRVA is below the current ROIC(2.75%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.67% | ||
| ROE | 3.11% | ||
| ROIC | 2.75% |
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
1.3 Margins
- PRVA has a Profit Margin (1.08%) which is in line with its industry peers.
- PRVA's Profit Margin has declined in the last couple of years.
- PRVA has a Operating Margin (1.61%) which is comparable to the rest of the industry.
- PRVA's Operating Margin has declined in the last couple of years.
- PRVA has a worse Gross Margin (9.87%) than 75.00% of its industry peers.
- PRVA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.61% | ||
| PM (TTM) | 1.08% | ||
| GM | 9.87% |
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
2. PRVA Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRVA is destroying value.
- Compared to 1 year ago, PRVA has more shares outstanding
- Compared to 5 years ago, PRVA has more shares outstanding
- There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- PRVA has an Altman-Z score of 4.27. This indicates that PRVA is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of PRVA (4.27) is better than 81.00% of its industry peers.
- PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.27 |
ROIC/WACC0.3
WACC9.03%
2.3 Liquidity
- PRVA has a Current Ratio of 1.60. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of PRVA (1.60) is better than 65.00% of its industry peers.
- PRVA has a Quick Ratio of 1.60. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
- With a decent Quick ratio value of 1.60, PRVA is doing good in the industry, outperforming 67.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 |
3. PRVA Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 54.55% over the past year.
- Measured over the past years, PRVA shows a decrease in Earnings Per Share. The EPS has been decreasing by -9.93% on average per year.
- PRVA shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.26%.
- PRVA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.04% yearly.
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%
3.2 Future
- The Earnings Per Share is expected to grow by 57.20% on average over the next years. This is a very strong growth
- Based on estimates for the next years, PRVA will show a quite strong growth in Revenue. The Revenue will grow by 10.44% on average per year.
EPS Next Y106.06%
EPS Next 2Y65.53%
EPS Next 3Y57.2%
EPS Next 5YN/A
Revenue Next Year13.79%
Revenue Next 2Y12.12%
Revenue Next 3Y11.91%
Revenue Next 5Y10.44%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. PRVA Valuation Analysis
4.1 Price/Earnings Ratio
- PRVA is valuated quite expensively with a Price/Earnings ratio of 126.59.
- PRVA's Price/Earnings ratio is in line with the industry average.
- PRVA is valuated expensively when we compare the Price/Earnings ratio to 25.54, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 61.43 indicates a quite expensive valuation of PRVA.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of PRVA is on the same level as its industry peers.
- The average S&P500 Price/Forward Earnings ratio is at 22.70. PRVA is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 126.59 | ||
| Fwd PE | 61.43 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PRVA is valued a bit more expensive than the industry average as 61.00% of the companies are valued more cheaply.
- Based on the Price/Free Cash Flow ratio, PRVA is valued a bit cheaper than 70.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.29 | ||
| EV/EBITDA | 48.65 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- PRVA's earnings are expected to grow with 57.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.19
PEG (5Y)N/A
EPS Next 2Y65.53%
EPS Next 3Y57.2%
5. PRVA Dividend Analysis
5.1 Amount
- No dividends for PRVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PRVA Fundamentals: All Metrics, Ratios and Statistics
21.52
+0.28 (+1.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)05-06 2026-05-06/bmo
Inst Owners99.61%
Inst Owner Change0.49%
Ins Owners1.85%
Ins Owner Change5.21%
Market Cap2.66B
Revenue(TTM)2.12B
Net Income(TTM)22.92M
Analysts84.29
Price Target32.15 (49.4%)
Short Float %2.15%
Short Ratio3.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)43.55%
Min EPS beat(2)-8.97%
Max EPS beat(2)96.08%
EPS beat(4)1
Avg EPS beat(4)-2.92%
Min EPS beat(4)-60.96%
Max EPS beat(4)96.08%
EPS beat(8)1
Avg EPS beat(8)-23.29%
EPS beat(12)3
Avg EPS beat(12)-1.19%
EPS beat(16)6
Avg EPS beat(16)61.33%
Revenue beat(2)1
Avg Revenue beat(2)5.86%
Min Revenue beat(2)-6.18%
Max Revenue beat(2)17.91%
Revenue beat(4)3
Avg Revenue beat(4)4.55%
Min Revenue beat(4)-6.18%
Max Revenue beat(4)17.91%
Revenue beat(8)7
Avg Revenue beat(8)4.33%
Revenue beat(12)10
Avg Revenue beat(12)3.07%
Revenue beat(16)10
Avg Revenue beat(16)-7.25%
PT rev (1m)0%
PT rev (3m)-0.08%
EPS NQ rev (1m)13.87%
EPS NQ rev (3m)13.87%
EPS NY rev (1m)8.83%
EPS NY rev (3m)9.32%
Revenue NQ rev (1m)-4.38%
Revenue NQ rev (3m)-31.33%
Revenue NY rev (1m)0.25%
Revenue NY rev (3m)-37.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 126.59 | ||
| Fwd PE | 61.43 | ||
| P/S | 1.25 | ||
| P/FCF | 16.29 | ||
| P/OCF | 16.29 | ||
| P/B | 3.61 | ||
| P/tB | 8.55 | ||
| EV/EBITDA | 48.65 |
EPS(TTM)0.17
EY0.79%
EPS(NY)0.35
Fwd EY1.63%
FCF(TTM)1.32
FCFY6.14%
OCF(TTM)1.32
OCFY6.14%
SpS17.16
BVpS5.96
TBVpS2.52
PEG (NY)1.19
PEG (5Y)N/A
Graham Number4.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.67% | ||
| ROE | 3.11% | ||
| ROCE | 4.27% | ||
| ROIC | 2.75% | ||
| ROICexc | 6.87% | ||
| ROICexgc | N/A | ||
| OM | 1.61% | ||
| PM (TTM) | 1.08% | ||
| GM | 9.87% | ||
| FCFM | 7.7% |
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
ROICexc(3y)6.14%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.37%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-16.37%
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
F-Score6
Asset Turnover1.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 136.39 | ||
| Cash Conversion | 370.18% | ||
| Profit Quality | 712.96% | ||
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z | 4.27 |
F-Score6
WACC9.03%
ROIC/WACC0.3
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)607.4%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
EPS Next Y106.06%
EPS Next 2Y65.53%
EPS Next 3Y57.2%
EPS Next 5YN/A
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%
Revenue Next Year13.79%
Revenue Next 2Y12.12%
Revenue Next 3Y11.91%
Revenue Next 5Y10.44%
EBIT growth 1Y101.6%
EBIT growth 3YN/A
EBIT growth 5Y6.15%
EBIT Next Year470.08%
EBIT Next 3Y100.08%
EBIT Next 5Y56.77%
FCF growth 1Y49.53%
FCF growth 3Y51.38%
FCF growth 5Y33.52%
OCF growth 1Y49.53%
OCF growth 3Y51.28%
OCF growth 5Y33.26%
PRIVIA HEALTH GROUP INC / PRVA Fundamental Analysis FAQ
What is the fundamental rating for PRVA stock?
ChartMill assigns a fundamental rating of 5 / 10 to PRVA.
Can you provide the valuation status for PRIVIA HEALTH GROUP INC?
ChartMill assigns a valuation rating of 3 / 10 to PRIVIA HEALTH GROUP INC (PRVA). This can be considered as Overvalued.
Can you provide the profitability details for PRIVIA HEALTH GROUP INC?
PRIVIA HEALTH GROUP INC (PRVA) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for PRVA stock?
The Price/Earnings (PE) ratio for PRIVIA HEALTH GROUP INC (PRVA) is 126.59 and the Price/Book (PB) ratio is 3.61.
Can you provide the financial health for PRVA stock?
The financial health rating of PRIVIA HEALTH GROUP INC (PRVA) is 7 / 10.